

**Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting**

*600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219*

Thursday, September 15, 2022 - 10:00 a.m.

Welcome and Comments from DMAS' Director

Chethan Bachireddy, MD, CMO, Chair

Call to Order

Chethan Bachireddy, MD, CMO, Chair

Drug Utilization Review (DUR) Board Update

Rachel Cain, PharmD

Health Equity and Disparities

John Morgan, MD, Chief Clinical Innovation Officer

Approval of Minutes from March 17, 2022, Meeting

P&T Committee Members

PDL Management

P&T Committee Members

Old business

- Bylaws
- Physician Administered Drugs

Phase II – New Drug Review (Therapeutic Class)

Brand Drugs

- Twyneo[®] topical (Acne Agents, Topical)
- Zimhi[™] (Opiate Dependence Treatments) (closed)
- Epsolay[®] (Rosacea Agents, Topical)
- Fleqsuvy[™] & Lyvispah[™] (Skeletal Muscle Relaxants)

Generics Drugs and New Dosage Forms

- tramadol Solution; generic (AG) for Qdolo[®] (Analgesics, Narcotics Short)
- lacosamide; generics Vimpat[®] tablets (Anticonvulsants)
- vilazodone generic for Viibryd[®] (Antidepressants, Other)
- Citalopram[®] HBR 30mg (Antidepressants, SSRIS)
- Takhzyro[®] Syringe (HAE Treatments)
- insulin glargine Solostar generic Lantus[®] Solostar and insulin glargine generic for Lantus[®] (Insulin And Related Agents)
- metformin HCL generic for Glucophage[®] (Metformin's)
- diclofenac 2% topical sol generic Pennsaid[®] and diclofenac potassium generic Zipsor[™] (NSAIDS)
- naloxone HCL 4 mg nasal spray generic Narcan[®] (Opiate Dependence Treatments)
- amlodipine-atorvastatin generic (AG) for Caduet[®] (Statins)
- clocortolone pivalate generic for Cloderm[®], topical (Steroids, Topical Medium)

Potential New PDL Closed Classes

- Glucagon Agents (Potential new PDL Closed Class)
- Hemophilia Treatment (Potential new PDL Closed Class)

- Sickle Cell Anemia Treatments (Potential new PDL Closed Class)
- Weight Management Agents (Potential new PDL Closed Class)

PDL Phase I – Annual Review -

Antibiotics/Anti-Infectives

- Antibiotics, Vaginal

Antivirals

- Hepatitis C Agents (Closed Class)
- HIV (Closed Class)

Blood Modifiers

- Bile Salts
- Phosphate Binders

Cardiac Medications

- Angiotensin Modulators (includes ACEs, ARBs, & CCB combination products)
- Angiotensin Modulators II (includes Direct Renin Inhibitors & combination products)
- Antihypertensives, Sympatholytics (Closed Class)
- Beta Blockers (includes combination products)
- Calcium Channel Blockers (includes dihydropyridine and non-dihydropyridine agents)
- Lipotropics, Statins
- Lipotropics, Other (includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibrin Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents)
- Pulmonary Arterial Hypertension Agents, Oral/Inhaled/Injectable (includes Endothelin-1 agents, PDE-5 Inhibitors, Prostacyclin analogues, Prostacyclin Vasodilator, Soluble Guanylate Cyclase Stimulators)

Central Nervous System

- Alzheimer's Agents
- Anticonvulsants (Closed class)
- Antipsychotics (includes oral and long acting injectables) This class will be reviewed in the Spring.
- Antidepressants, SSRI
- Antidepressants, Other
- Movement Disorder Agents (Closed Class)
- Sedative Hypnotics

Dermatitis

- Immunomodulators, Atopic Dermatitis (Closed Class)
- Steroids, Topical

Endocrine & Metabolic Agents

- Glucocorticoids, Oral
- Growth Hormones (Closed Class)
- Hereditary Angioedema (HAE)
- Progestins for Cachexia

Gastrointestinal

- Antiemetic/Antivertigo Agents
- GI Motility, Chronic
- H. pylori Agents

- Histamine-2 Receptor Antagonists (H-2RA)
- Proton Pump Inhibitors
- Ulcerative Colitis

Genitourinary

- Bladder Relaxants
- BPH Agents (includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitors for BPH treatment)

Ophthalmic

- Allergic Conjunctivitis (includes Ophthalmic Antihistamines & Mast Cell Stabilizers)
- Antibiotics
- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (includes Ophthalmic NSAIDS & Corticosteroids)
- Anti-inflammatory/ immunomodulators (*Closed Class*)
- Glaucoma Agents (*includes Alpha-2 Adrenergics, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors*)

Respiratory

- Anti-Allergens
- Antibiotics, Inhaled (*Closed Class*)
- Antihistamines Minimally Sedating
- Bronchodilators, Long-Acting Beta Adrenergics
- Bronchodilators, Short Acting Beta Adrenergics
- COPD (*includes Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors*) (*Closed Class*)
- Cough & Cold Agents (*Legend*)
- Epinephrine, Self-Injected
- Glucocorticoids (*includes nebulized solutions, metered dose inhalers and combinations*) (*Closed Class*)
- Intranasal Rhinitis (includes Antihistamines and Corticosteroids)
- Leukotriene Modifiers

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

PDL Recommendations and Vote

P&T Committee Members

Criteria Discussion of Phase II New Drugs*

P&T Committee Members

Criteria Discussion of PDL Phase I Drug Classes*

P&T Committee Members

Next Meeting - tentatively scheduled for March 16, 2023

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will allocate time slots for interested parties to present scientific and clinical information on PDL Phase I drugs in classes in which are scheduled for review at the September meeting and new PDL Phase II drugs listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Reviews – September 2021 to present

- **New Drugs in PDL Phase I or II Drug Classes – September 2020 to present**
- **Potential new drug classes– September 2020 to present**

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The Chairperson will approve presentation requests based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must **submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter.** Please send requested information to pdlinput@dmas.virginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on Thursday, August 18, 2022.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by 5 p.m. EST on Thursday, August 18, 2022.

DRAFT